EP3390443A4 - Anticorps anti-myostatine, polypeptides contenant des variants de régions fc, et procédés d'utilisation - Google Patents

Anticorps anti-myostatine, polypeptides contenant des variants de régions fc, et procédés d'utilisation Download PDF

Info

Publication number
EP3390443A4
EP3390443A4 EP16875757.3A EP16875757A EP3390443A4 EP 3390443 A4 EP3390443 A4 EP 3390443A4 EP 16875757 A EP16875757 A EP 16875757A EP 3390443 A4 EP3390443 A4 EP 3390443A4
Authority
EP
European Patent Office
Prior art keywords
regions
methods
polypeptides containing
myostatin antibodies
containing variant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP16875757.3A
Other languages
German (de)
English (en)
Other versions
EP3390443A1 (fr
Inventor
Taichi Kuramochi
Tomoyuki Igawa
Hitoshi KATADA
Yuji Hori
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chugai Pharmaceutical Co Ltd
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of EP3390443A1 publication Critical patent/EP3390443A1/fr
Publication of EP3390443A4 publication Critical patent/EP3390443A4/fr
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP16875757.3A 2015-12-18 2016-12-16 Anticorps anti-myostatine, polypeptides contenant des variants de régions fc, et procédés d'utilisation Pending EP3390443A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2015247070 2015-12-18
PCT/JP2016/087487 WO2017104783A1 (fr) 2015-12-18 2016-12-16 Anticorps anti-myostatine, polypeptides contenant des variants de régions fc, et procédés d'utilisation

Publications (2)

Publication Number Publication Date
EP3390443A1 EP3390443A1 (fr) 2018-10-24
EP3390443A4 true EP3390443A4 (fr) 2019-11-13

Family

ID=59011957

Family Applications (1)

Application Number Title Priority Date Filing Date
EP16875757.3A Pending EP3390443A4 (fr) 2015-12-18 2016-12-16 Anticorps anti-myostatine, polypeptides contenant des variants de régions fc, et procédés d'utilisation

Country Status (16)

Country Link
EP (1) EP3390443A4 (fr)
JP (4) JP6142069B1 (fr)
KR (4) KR102501335B1 (fr)
CN (2) CN108473562B (fr)
AR (1) AR107078A1 (fr)
AU (1) AU2016372934B2 (fr)
BR (1) BR112018011073A2 (fr)
CA (1) CA3002422C (fr)
EA (1) EA201891420A1 (fr)
HK (1) HK1254755A1 (fr)
MX (1) MX2018007145A (fr)
MY (1) MY189425A (fr)
PH (1) PH12018501280A1 (fr)
SG (2) SG10201707267RA (fr)
TW (3) TWI749057B (fr)
WO (1) WO2017104783A1 (fr)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101479381B (zh) 2006-03-31 2015-04-29 中外制药株式会社 调控抗体血液动力学的方法
US9096651B2 (en) 2007-09-26 2015-08-04 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substitution in CDR
CN103251948A (zh) 2008-04-11 2013-08-21 中外制药株式会社 与多个分子的抗原反复结合的抗原结合分子
CN107973851A (zh) 2010-11-30 2018-05-01 中外制药株式会社 与多分子的抗原重复结合的抗原结合分子
KR20150016579A (ko) 2012-05-30 2015-02-12 추가이 세이야쿠 가부시키가이샤 표적 조직 특이적 항원 결합 분자
WO2014030750A1 (fr) 2012-08-24 2014-02-27 中外製薬株式会社 ANTICORPS Fc SPÉCIFIQUE À FcyRII DE SOURIS
TWI717591B (zh) 2012-08-24 2021-02-01 日商中外製藥股份有限公司 ＦｃγＲＩＩｂ特異性Ｆｃ區域變異體
CA2908350C (fr) 2013-04-02 2023-08-08 Futa Mimoto Variant de region fc
AU2014358191B2 (en) 2013-12-04 2020-12-24 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecules, the antigen-binding activity of which varies according to the concentration of compounds, and libraries of said molecules
MA41294A (fr) 2014-12-19 2017-11-08 Chugai Pharmaceutical Co Ltd Anticorps anti-myostatine, polypeptides contenant des variants de régions fc, et procédés d'utilisation
WO2016125495A1 (fr) 2015-02-05 2016-08-11 Chugai Seiyaku Kabushiki Kaisha Anticorps comprenant un domaine se liant à l'antigène dépendant de la concentration d'ions, variants de la région fc, anticorps se liant à l'il-8, et leurs utilisations
TWI749057B (zh) * 2015-12-18 2021-12-11 日商中外製藥股份有限公司 抗肌抑素抗體、含變異ｆｃ區之多肽及使用方法
US11359009B2 (en) 2015-12-25 2022-06-14 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies and methods of use
TW202228778A (zh) * 2016-06-17 2022-08-01 日商中外製藥股份有限公司 抗肌抑素抗體及使用方法
RU2766112C2 (ru) 2016-08-05 2022-02-08 Чугаи Сейяку Кабусики Кайся Композиция для профилактики или лечения связанных с il-8 заболеваний
MX2019010028A (es) 2017-02-28 2019-10-14 Seattle Genetics Inc Anticuerpos con cisteina mutada por conjugacion.
SG10202106830VA (en) 2018-08-10 2021-08-30 Chugai Pharmaceutical Co Ltd Anti-cd137 antigen-binding molecule and utilization thereof
CN113906042A (zh) * 2019-04-10 2022-01-07 中外制药株式会社 用于纯化fc区修饰抗体的方法
KR20220093103A (ko) * 2019-09-13 2022-07-05 어드메어 테라퓨틱스 소사이어티 항종양용해 바이러스 항원 항체 및 이의 사용 방법
RU2750267C1 (ru) * 2020-02-07 2021-06-25 Общество с ограниченной ответственностью «НАУЧНО-ПРОИЗВОДСТВЕННОЕ ОБЪЕДИНЕНИЕ ИН-ВЕТ» Рекомбинантный ростовой дифференцировочный фактор роста 11 (GDF11), способ его получения, инъекционный препарат для повышения мышечной массы млекопитающих животных и птицы, а также способ использования препарата
TW202144395A (zh) 2020-02-12 2021-12-01 日商中外製藥股份有限公司 用於癌症之治療的抗cd137抗原結合分子
CN118055767A (zh) 2021-10-06 2024-05-17 豪夫迈·罗氏有限公司 新颖的组合施用
TW202346345A (zh) 2022-04-01 2023-12-01 瑞士商赫孚孟拉羅股份公司 面肩胛肱肌失養症（ｆｓｈｄ）之新治療
TWI833641B (zh) 2022-05-02 2024-02-21 丹麥商諾佛 儂迪克股份有限公司 適於高濃度組成物及皮下投藥之新穎抗ａｎｇｐｔｌ３抗體
US20240173325A1 (en) 2022-10-14 2024-05-30 Genentech, Inc. Methods for treating spinal muscular atrophy
CN116990528B (zh) * 2023-09-27 2024-02-06 成都华西海圻医药科技有限公司 一种基于Gyrolab平台快速测定抗CD40单抗的分析方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003027248A2 (fr) * 2001-09-26 2003-04-03 Wyeth Anticorps inhibiteurs de gdf-8 et utilisations associees
EP2889377A1 (fr) * 2012-08-24 2015-07-01 Chugai Seiyaku Kabushiki Kaisha Variant de la région fc spécifique à fcyriib
EP3240804A1 (fr) * 2014-12-19 2017-11-08 Chugai Seiyaku Kabushiki Kaisha Anticorps anti-myostatine, polypeptides contenant des variants de régions fc, et procédés d'utilisation

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR047392A1 (es) * 2002-10-22 2006-01-18 Wyeth Corp Neutralizacion de anticuerpos contra gdf 8 y su uso para tales fines
CA2580796C (fr) * 2004-09-24 2013-03-26 Amgen Inc. Molecules fc modifiees ayant des peptides inserees dans les regions de boucle interne
US8008453B2 (en) * 2005-08-12 2011-08-30 Amgen Inc. Modified Fc molecules
CN101511871B (zh) * 2006-09-05 2012-07-18 伊莱利利公司 抗肌肉生长抑制因子抗体
PE20091163A1 (es) * 2007-11-01 2009-08-09 Wyeth Corp Anticuerpos para gdf8
CN103251948A (zh) 2008-04-11 2013-08-21 中外制药株式会社 与多个分子的抗原反复结合的抗原结合分子
TW201029662A (en) 2008-12-19 2010-08-16 Glaxo Group Ltd Novel antigen binding proteins
SG183867A1 (en) * 2010-03-11 2012-10-30 Rinat Neuroscience Corp ANTIBODIES WITH pH DEPENDENT ANTIGEN BINDING
AR081556A1 (es) * 2010-06-03 2012-10-03 Glaxo Group Ltd Proteinas de union al antigeno humanizadas
US9334334B2 (en) * 2012-03-16 2016-05-10 Regeneron Pharmaceuticals, Inc. Histidine engineered light chain antibodies and genetically modified non-human animals for generating the same
TWI619729B (zh) * 2012-04-02 2018-04-01 再生元醫藥公司 抗－ｈｌａ－ｂ*２７抗體及其用途
AR092098A1 (es) * 2012-08-13 2015-03-25 Regeneron Pharma ANTICUERPOS ANTI-PCSK9 CON CARACTERISTICAS DE UNION DEPENDIENTES DEL pH
WO2014182676A2 (fr) * 2013-05-06 2014-11-13 Scholar Rock, Inc. Compositions et procédés de modulation du facteur de croissance
SG11201600212VA (en) * 2013-08-14 2016-02-26 Novartis Ag Methods of treating sporadic inclusion body myositis
EP3215175A4 (fr) * 2014-11-06 2018-06-27 Scholar Rock, Inc. Anticorps anti-pro-myostatine/myostatine latente et leurs utilisations
WO2016073879A2 (fr) * 2014-11-06 2016-05-12 Scholar Rock, Inc. Anticorps liés à des facteurs de croissance transformants et utilisations de ceux-ci
TWI749057B (zh) 2015-12-18 2021-12-11 日商中外製藥股份有限公司 抗肌抑素抗體、含變異ｆｃ區之多肽及使用方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003027248A2 (fr) * 2001-09-26 2003-04-03 Wyeth Anticorps inhibiteurs de gdf-8 et utilisations associees
EP2889377A1 (fr) * 2012-08-24 2015-07-01 Chugai Seiyaku Kabushiki Kaisha Variant de la région fc spécifique à fcyriib
EP3240804A1 (fr) * 2014-12-19 2017-11-08 Chugai Seiyaku Kabushiki Kaisha Anticorps anti-myostatine, polypeptides contenant des variants de régions fc, et procédés d'utilisation

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JOHN O RICHARDS ET AL: "Optimization of antibody binding to FcãRIIa enhances macrophage phagocytosis of tumor cells", MOLECULAR CANCER THERAPEUTICS, AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 7, no. 8, 1 August 2008 (2008-08-01), pages 2517 - 2527, XP002631327, ISSN: 1535-7163, DOI: 10.1158/1535-7163.MCT-08-0201 *

Also Published As

Publication number Publication date
AU2016372934A1 (en) 2018-05-10
JP7053164B2 (ja) 2022-04-12
TW201808992A (zh) 2018-03-16
CN115028721A (zh) 2022-09-09
KR20230027321A (ko) 2023-02-27
AR107078A1 (es) 2018-03-21
JP2022097485A (ja) 2022-06-30
MY189425A (en) 2022-02-10
PH12018501280A1 (en) 2019-01-28
KR101820637B1 (ko) 2018-01-19
JP2017148069A (ja) 2017-08-31
SG10201707267RA (en) 2017-10-30
TWI605057B (zh) 2017-11-11
JP2024023427A (ja) 2024-02-21
TW201726718A (zh) 2017-08-01
CN108473562B (zh) 2022-06-17
AU2016372934B2 (en) 2023-10-05
JP2017112997A (ja) 2017-06-29
CN108473562A (zh) 2018-08-31
TW202231662A (zh) 2022-08-16
CA3002422C (fr) 2024-04-16
KR20180085711A (ko) 2018-07-27
EP3390443A1 (fr) 2018-10-24
SG11201610812WA (en) 2017-07-28
BR112018011073A2 (pt) 2018-11-21
MX2018007145A (es) 2018-08-15
RU2018125431A (ru) 2020-01-20
KR102501335B1 (ko) 2023-02-17
KR20240058997A (ko) 2024-05-03
EA201891420A1 (ru) 2019-02-28
HK1254755A1 (zh) 2019-07-26
JP6142069B1 (ja) 2017-06-07
KR20170085028A (ko) 2017-07-21
TWI749057B (zh) 2021-12-11
WO2017104783A1 (fr) 2017-06-22
CA3002422A1 (fr) 2017-06-22
RU2018125431A3 (fr) 2020-07-06

Similar Documents

Publication Publication Date Title
IL278014A (en) Anti-myostatin antibodies, polypeptides containing variable FC regions and methods of use
HK1254755A1 (zh) 抗-肌肉生長抑制因子抗體、包含變體fc區的多肽及使用方法
IL264590A (en) fc region-containing polypeptides and uses thereof
EP3472200A4 (fr) Anticorps anti-myostatine et leurs procédés d'utilisation
EP3377102A4 (fr) Anticorps anti-pd-1 et leurs utilisations thérapeutiques
EP3299383A4 (fr) MODIFICATION SPÉCIFIQUE DE L'ANTICORPS PAR UN PEPTIDE DE LIAISON À IgG
EP3137505A4 (fr) Combinaison de lénalidomide et d'une construction de polypeptide, et ses utilisations
EP3241850A4 (fr) Polypeptide de fusion de glp et d'un fc hybride d'immunoglobuline, et utilisation de ce dernier
EP3237450A4 (fr) Anticorps agonistes anti-mertk et leurs utilisations
EP3512879A4 (fr) Anticorps antivirus de la dengue, polypeptides contenant des variants de régions fc, et procédés d'utilisation
EP3122783A4 (fr) Nouvelles protéines de fusion bifonctionnelles recombinées, leur préparation et leur utilisation
EP3394098A4 (fr) Anticorps anti-myostatine et procédés d'utilisation
EP3104870A4 (fr) Peptides tau, anticorps anti-tau, et leurs procédés d'utilisation
EP3236772A4 (fr) Procédés permettant de purifier des protéines recombinantes
EP3328429A4 (fr) Peptides et anticorps pour l'élimination de biofilms
EP3233916A4 (fr) Anticorps anti-acth humanisés et leur utilisation
EP3341021A4 (fr) Anticorps anti-alk et leurs procédés d'utilisation
EP3280440A4 (fr) Anticorps anti-c1s humanisés et leurs procédés d'utilisation
EP3400239A4 (fr) Anticorps tétravalents contre psgl-1 et utilisations de ces derniers
EP3315515A4 (fr) Protéine hybride contenant un bdnf
EP3199179A4 (fr) Formulation de protéines hybrides recombinantes
EP3199555A4 (fr) Formulation de protéines hybrides recombinantes
EP3285805A4 (fr) Anticorps thérapeutiques et utilisations de ceux-ci
EP3270918A4 (fr) Anticorps anti-met et procédés d'utilisation de ceux-ci
EP3096784A4 (fr) Peptides, dispositifs et procédés pour la détection d'anticorps d'anaplasma

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20180717

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: C07K 16/18 20060101AFI20190723BHEP

Ipc: C12N 15/09 20060101ALI20190723BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20191014

RIC1 Information provided on ipc code assigned before grant

Ipc: C07K 16/18 20060101AFI20191008BHEP

Ipc: C12N 15/09 20060101ALI20191008BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20200921

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS